- The European Commission (EC) approves AstraZeneca's (NASDAQ:AZN) Lynparza (olaparib) for first-line maintenance treatment with bevacizumab [Roche's (OTCQX:RHHBY) Avastin] of patients with homologous recombination deficient (HRD)-positive advanced ovarian cancer and patients with metastatic castration-resistant prostate cancer (mCRPC) with breast cancer susceptibility gene 1/2 (BRCA1/2) mutations, a subpopulation of homologous recombination repair (HRR) gene mutations.
- The EC also approves Forxiga (dapagliflozin) for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF) in adults with and without type-2 diabetes.
- Related ticker: Merck (NYSE:MRK)
- https://seekingalpha.com/news/3631978-astrazeneca-nabs-new-approvals-in-europe
Thursday, November 5, 2020
AstraZeneca nabs new approvals in Europe
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.